Coherus BioSciences, Inc. (CHRS) announced on Wednesday the final results of its Phase 2 trial assessing the efficacy of casdozokitug in conjunction with atezolizumab and bevacizumab for patients with hepatocellular carcinoma (HCC), a form of liver cancer.
According to the final data, the overall response rate improved to 38% from the initially reported 27%, while complete responses (CR) increased to 17.2% from 10.3%. Additionally, the combination treatment was well-tolerated, showing a side effect profile consistent with the known adverse effects of atezolizumab and bevacizumab.
These findings provide a basis for further investigation of casdozokitug in combination with other therapies. This includes a newly initiated trial combining casdozokitug, toripalimab, and bevacizumab for HCC, for which Coherus has commenced enrollment, the company stated.
